Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) was founded in 2005 and is headquartered in Chicago, Illinois, with 55 full-time employees (5/31/2018). It is a professional pharmaceutical company that uses the company’s new non-aqueous formulation technology platform XeriSol and XeriJect develops and commercializes ready-to-use, injectable and non-infusible pharmaceutical formulations.
Xeris Pharmaceuticals, Inc. (XERS):
Xeris Pharmaceuticals, Inc. has developed a ready-to-use room temperature stable liquid glucagon preparation, which is different from any existing products in that it can be administered without any preparation or reformulation.
Xeris Pharmaceuticals’ main product candidate, Glucagon Rescue Pen (glucagon emergency pen), provides diabetic patients with ready-to-use glucagon through a commercially available auto-injector for the treatment of severe hypoglycemia, which is a potential Life-threatening diseases.
Xeris Pharmaceuticals has completed three phase III clinical trials for its glucagon emergency pen and expects to submit a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2018. If the company’s NDA is submitted and approved within the expected time frame, Xeris Pharmaceuticals will have the first ready-to-use, room-temperature stable liquid glucagon formulation that can be administered without any preparation or reconstitution.
Xeris Pharmaceuticals also applies its new ready-to-use room temperature stable liquid glucagon preparations to manage other conditions related to hypoglycemia and to meet major unmet medical needs. In addition, Xeris Pharmaceuticals is applying its technology platform to convert other commercial drugs into ready-to-use room temperature stable liquid formulations to meet the needs of a variety of therapeutic areas and conditions, including epilepsy and diabetes.
Xeris Pharmaceuticals, Inc. (XERS) investment:
Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) submitted its IPO prospectus on 5/24/2018 and listed on NASDAQ on 6/21/2018 iPo, with an issue price of US$15.00, 5.7 million shares issued, and a fund-raising of US$85.5 million.